BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 10583407)

  • 1. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth.
    McLaurin J; Franklin T; Zhang X; Deng J; Fraser PE
    Eur J Biochem; 1999 Dec; 266(3):1101-10. PubMed ID: 10583407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of amino-acid substitutions on Alzheimer's amyloid-beta peptide-glycosaminoglycan interactions.
    McLaurin J; Fraser PE
    Eur J Biochem; 2000 Nov; 267(21):6353-61. PubMed ID: 11029577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sulfated proteoglycan aggregation factor mediates amyloid-beta peptide fibril formation and neurotoxicity.
    McLaurin J; Franklin T; Kuhns WJ; Fraser PE
    Amyloid; 1999 Dec; 6(4):233-43. PubMed ID: 10611943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ca(2+), within the physiological concentrations, selectively accelerates Abeta42 fibril formation and not Abeta40 in vitro.
    Ahmad A; Muzaffar M; Ingram VM
    Biochim Biophys Acta; 2009 Oct; 1794(10):1537-48. PubMed ID: 19595795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans.
    Brunden KR; Richter-Cook NJ; Chaturvedi N; Frederickson RC
    J Neurochem; 1993 Dec; 61(6):2147-54. PubMed ID: 8245966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions.
    Fraser PE; Nguyen JT; Chin DT; Kirschner DA
    J Neurochem; 1992 Oct; 59(4):1531-40. PubMed ID: 1402902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling.
    Gu L; Tran J; Jiang L; Guo Z
    J Struct Biol; 2016 Apr; 194(1):61-7. PubMed ID: 26827680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.
    Castillo GM; Ngo C; Cummings J; Wight TN; Snow AD
    J Neurochem; 1997 Dec; 69(6):2452-65. PubMed ID: 9375678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes.
    Qiang W; Yau WM; Lu JX; Collinge J; Tycko R
    Nature; 2017 Jan; 541(7636):217-221. PubMed ID: 28052060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of Nucleated Conformational Conversion of Aβ42.
    Fu Z; Aucoin D; Davis J; Van Nostrand WE; Smith SO
    Biochemistry; 2015 Jul; 54(27):4197-207. PubMed ID: 26069943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The protective effect of crocin on the amyloid fibril formation of Aβ42 peptide in vitro.
    Ghahghaei A; Bathaie SZ; Kheirkhah H; Bahraminejad E
    Cell Mol Biol Lett; 2013 Sep; 18(3):328-39. PubMed ID: 23737042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous in vitro formation of supramolecular beta-amyloid structures, "betaamy balls", by beta-amyloid 1-40 peptide.
    Westlind-Danielsson A; Arnerup G
    Biochemistry; 2001 Dec; 40(49):14736-43. PubMed ID: 11732892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues.
    Gordon DJ; Sciarretta KL; Meredith SC
    Biochemistry; 2001 Jul; 40(28):8237-45. PubMed ID: 11444969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation.
    Castillo GM; Lukito W; Wight TN; Snow AD
    J Neurochem; 1999 Apr; 72(4):1681-7. PubMed ID: 10098877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential inhibitory effect of β-casein on the aggregation and deposition of Aβ
    Hojati S; Ghahghaei A; Lagzian M
    J Biomol Struct Dyn; 2018 Jun; 36(8):2118-2130. PubMed ID: 28633568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel glycosaminoglycan precursors as anti-amyloid agents part II.
    Kisilevsky R; Szarek WA
    J Mol Neurosci; 2002; 19(1-2):45-50. PubMed ID: 12212792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-induced aggregation and precipitation of soluble proteins: an electrostatic contribution of the Alzheimer's beta(25-35) amyloid fibril.
    Konno T
    Biochemistry; 2001 Feb; 40(7):2148-54. PubMed ID: 11329283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolines and amyloidogenicity in fragments of the Alzheimer's peptide beta/A4.
    Wood SJ; Wetzel R; Martin JD; Hurle MR
    Biochemistry; 1995 Jan; 34(3):724-30. PubMed ID: 7827029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-like fibril formation by tachykinin neuropeptides and its relevance to amyloid β-protein aggregation and toxicity.
    Singh PK; Maji SK
    Cell Biochem Biophys; 2012 Sep; 64(1):29-44. PubMed ID: 22628076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide.
    Cottingham MG; Hollinshead MS; Vaux DJ
    Biochemistry; 2002 Nov; 41(46):13539-47. PubMed ID: 12427014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.